---
title: 30–90 Day Inspection Ready Validated SaaS Deployment for Pharma QA
date: 2026-10-08
description: QA and validation leads: a 30–90 day inspection ready playbook that maps Annex 11 and FDA CSA to URS, RTM, executed tests, and ALCOA+ audit trails, plus...
author: Qualitum
cover: https://media.babylovegrowth.ai/blog-images/organization-48457/1791281723776_Pharmaceutical-inspection-machine-in-cleanroom.jpeg
coverAlt: Pharmaceutical inspection machine in cleanroom
---

A validated SaaS deployment is a cloud service that has been qualified, documented, and controlled to meet GxP computer system validation expectations under Annex 11, 21 CFR Part 11, and where applicable, ISO 13485. Inspectors will ask for three things first: a requirements traceability matrix tied to executed test evidence, proof the vendor contract gives you access to validation documentation, and audit trails that hold up to ALCOA+ scrutiny.

***

> **TL;DR:**
>
> - Focus validation efforts on features that create, modify, or approve GxP records, while de-scoping non-regulated functions like dashboards and internal collaboration tools.
> - Maintain a lifecycle validation approach by classifying each system function as low, medium, or high risk and adjusting validation depth accordingly, revisiting this classification with system changes.
> - Ensure the traceability matrix links every requirement to a tested result and rebuild it after each vendor update to prevent configuration drift from breaking the chain.
> - Guarantee the contract with the SaaS vendor grants access to validation documentation, with clear SLAs, change notifications, and review rights, as these are critical for inspection readiness.
> - Use signed, dated test records and comprehensive audit trail extracts to reliably demonstrate compliance, reducing the risk of gaps that regulators frequently identify during inspections.

***

## Table of Contents

- [Quick inspection-ready checklist for validated SaaS deployments](#quick-inspection-ready-checklist-for-validated-saas-deployments)
- [Deciding which SaaS features actually require CSV](#deciding-which-saas-features-actually-require-csv)
- [Building a risk-based validation strategy that holds up over time](#building-a-risk-based-validation-strategy-that-holds-up-over-time)
- [Getting requirements and traceability right: URS to RTM to test scripts](#getting-requirements-and-traceability-right-urs-to-rtm-to-test-scripts)
- [Managing supplier contracts, SLAs, and audit access](#managing-supplier-contracts-slas-and-audit-access)
- [Proving verification with test records and ALCOA+ audit trails](#proving-verification-with-test-records-and-alcoa-audit-trails)
- [Keeping a validated SaaS deployment in a validated state](#keeping-a-validated-saas-deployment-in-a-validated-state)
- [Applying 21 CFR Part 11 and FDA CSA without overbuilding](#applying-21-cfr-part-11-and-fda-csa-without-overbuilding)
- [Your 30 to 90 day inspection-readiness checklist](#your-30-to-90-day-inspection-readiness-checklist)
- [What validation teams keep getting wrong in practice](#what-validation-teams-keep-getting-wrong-in-practice)
- [How we help teams reach inspection readiness faster](#how-we-help-teams-reach-inspection-readiness-faster)
- [FAQ](#faq)
- [Sources](#sources)
- [Authoritative guidance to consult directly](#authoritative-guidance-to-consult-directly)

## Quick inspection-ready checklist for validated SaaS deployments

When an inspector asks to see your validation package, speed matters as much as content. Pull these artifacts first:

- Approved user requirements specification (URS) signed off by the regulated user, not the vendor.
- Requirements traceability matrix (RTM) linking every requirement to a test case and a result.
- Executed test scripts with signed, dated results, not blank templates.
- Vendor validation package, including their internal testing evidence and change history.
- Current SLA or contract showing access rights to the vendor's validation documentation.
- Audit trail extracts covering the inspection period, formatted for review.
- Documented backup and restore test results.

Regulators treat the URS, RTM, and executed test evidence as essential, non-negotiable items. Backup and restore proof and supplier documentation are often weighed by risk level, but a missing RTM or unexplained gap in test traceability is the fastest way to turn a routine visit into a finding.

## Deciding which SaaS features actually require CSV

Not every feature inside a SaaS platform touches product quality or patient safety, and treating the whole system as equally in-scope wastes effort and obscures the controls that matter. The intended use of each function determines whether it needs full validation.

- Features that create, modify, or approve GxP records (batch release, deviation sign-off, document approval) are in-scope.

- Features limited to internal collaboration, scheduling, or non-regulated reporting are typically out-of-scope.

- Dashboards that aggregate validated data for decision-making usually need a lighter, risk-based check rather than full qualification.

Write a short intended-use statement and impact assessment for each major module before validation planning starts. The logic mirrors how [FDA's Computer Software Assurance guidance](https://www.fda.gov/media/188844/download) ties validation effort to whether a feature affects record integrity, product quality, or patient safety, rather than defaulting to maximum rigor everywhere.

## Building a risk-based validation strategy that holds up over time

Annex 11 and GAMP 5 both frame validation as a lifecycle obligation, not a one-time event: a system must be validated before use and kept in a validated state through every subsequent change. Quality risk management (QRM) applied consistently across that lifecycle lets you scale effort to actual risk instead of validating every feature at the same intensity.

1. Classify each function as low, medium, or high risk based on its effect on patient safety, product quality, and data integrity.
2. Size validation depth to that classification: low-risk administrative features need light documentation; high-risk functions like electronic batch records need full qualification and detailed test evidence.
3. Document the rationale in a validation plan, supported by a formal risk assessment and clear acceptance criteria.
4. Revisit the risk classification whenever the vendor changes the feature set or your intended use shifts.

The updated Annex 11 draft guidance makes this lifecycle expectation explicit, including requirements for QRM to be applied at each phase, not only at initial qualification. [ISPE GAMP 5](https://guidance-docs.ispe.org/doi/book/10.1002/9781946964571) (Second Edition) reinforces the same scalable, risk-based posture and explicitly recognizes the growing role of service providers in delivering compliant systems.

## Getting requirements and traceability right: URS to RTM to test scripts

Your URS should state functional needs, data integrity controls, security requirements, performance expectations, and interface points, written from the regulated user's perspective, not copied from vendor marketing. A configuration specification then documents exactly which settings, workflows, and permissions you've chosen within the vendor's platform.

- URS content: functional requirements, data integrity rules, access control, performance thresholds, interface and integration points.
- RTM structure: each requirement mapped to one or more test cases, each test case mapped to an executed result.
- Configuration control: a dated record of chosen settings, with version history when the vendor updates the platform.

The RTM is where most packages fall apart under scrutiny. [Annex 11 guidance](https://health.ec.europa.eu/document/download/40231f18-e564-4043-94de-c031f813d38b_en) is explicit that test cases must trace back to a documented requirement; an orphaned test or an untested requirement undermines the whole matrix.

**Pro Tip:** *Rebuild your RTM link-by-link after every vendor release, not just at initial validation, since configuration drift is the most common cause of a broken traceability chain.*

## Managing supplier contracts, SLAs, and audit access

A SaaS vendor's internal testing doesn't replace your validation obligation, but it does become part of your evidence package only if your contract guarantees access to it. Minimum contractual terms should cover:

- The right to review vendor validation documentation on request, including during a regulatory inspection.
- Advance notification of changes that could affect validated functionality.
- Clear delineation of roles and responsibilities between vendor and regulated user.
- SLA-defined uptime, response times, and data recovery commitments, with KPIs you can point to as operational evidence.

Where a formal supplier audit isn't feasible, document an alternative such as a vendor questionnaire, certification review, or documented reliance on the vendor's own quality system evidence. GAMP 5 treats this supplier relationship as a first-class part of the validation lifecycle, not an afterthought.

## Proving verification with test records and ALCOA+ audit trails

Acceptable execution evidence means signed, dated test reports tied to specific script versions, not screenshots taken after the fact or summary memos claiming tests passed. Where a step can't be captured automatically, a screen capture referenced in the executed script fills the gap.

- Executed test scripts with pass/fail results recorded at the time of execution.
- Signed test summary reports linking back to the RTM.
- Audit trail extracts covering the records under review, with a documented review frequency and a named reviewer role.
- Evidence that audit trail review actually happened, not just that the function exists.

**Common inspection focus areas include data integrity and audit trail completeness**, according to [industry GMP compliance guidance](https://www.gmp-compliance.org/files/guidemgr/PI%20041-1.pdf), which repeatedly flags audit trails and supplier documentation as recurring gaps during inspections. ALCOA+ checks performed at write-time (catching missing timestamps or unattributed entries as they happen) and again at review-time (confirming nothing was altered after the fact) close the gap between having an audit trail and being able to defend it.

## Keeping a validated SaaS deployment in a validated state

Validation doesn't end at go-live. Three operational controls keep the system defensible:

1. Change control that baselines the current validated configuration and re-assesses risk before any vendor update is accepted into production.
2. Scheduled backup and restore testing, with retention periods matched to your record retention requirements, not just the vendor's default settings.
3. Periodic evaluation covering upgrade history, performance trends, incident logs, and security posture, repeated on a defined schedule rather than only when a problem surfaces.

Skipping periodic evaluation is one of the fastest ways a previously validated system drifts out of compliance without anyone noticing until an inspection.

## Applying 21 CFR Part 11 and FDA CSA without overbuilding

Part 11 applies where a predicate rule requires the record, so the first question is always whether the underlying regulation demands that specific record, not whether the software happens to be electronic. [21 CFR Part 11](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11) sets the validation, audit trail, and signature controls that apply once that threshold is met.

- Tie each record type to its predicate rule before deciding Part 11 applies.
- Use FDA's CSA framework to size assurance effort to risk rather than defaulting to maximum documentation for every feature.
- Document the justification in your validation package, referencing the risk assessment directly, so an inspector can follow your reasoning rather than just your conclusion.

FDA's CSA guidance explicitly supports this least-burdensome approach, provided the rationale is written down and tied to intended use.

## Your 30 to 90 day inspection-readiness checklist

Work backward from the inspection date with a single owner assigned to each item:

1. Compile and reconcile the URS and RTM, closing any orphaned requirements or untested links.
2. Gather executed test evidence and confirm every script has a signed result.
3. Extract and format audit trails for the review period, confirming reviewer sign-off exists.
4. Confirm vendor contracts, SLAs, and validation package access are current.
5. Run a backup and restore test and document the result.

The fastest last-minute failures are an RTM with gaps, audit trails nobody reviewed, and a vendor contract silent on document access.

## What validation teams keep getting wrong in practice

![What validation teams keep getting wrong in practice — overview diagram](https://media.babylovegrowth.ai/blog-images/organization-48457/1791281775553_What-validation-teams-keep-getting-wrong-in-practice-overview-diagram.jpeg)

Auditors consistently prioritize traceability and evidence accessibility over polished formatting. A beautifully formatted validation report with a broken RTM fails faster than a plain one with solid links.

The recurring pitfalls are predictable: incomplete RTMs that lose their links after a configuration update, vendor evidence that was never actually requested, and audit trail reviews that exist on paper but never happened in practice. Automated ALCOA+ checks applied at both write-time and review-time catch many of these gaps before they reach an inspector, which is where automation earns its place in a validation program rather than replacing human judgment.

> *— Matt*

## How we help teams reach inspection readiness faster

We built Qualitum to close the gap between having validation documentation and being able to defend it on demand. Our platform authors validation lifecycle artifacts, including URS, test scripts, and the RTM, as a connected system rather than disconnected documents, and every record is ALCOA+ checked at write-time and again at review-time.

![Qualitum](https://csuxjmfbwmkxiegfpljm.supabase.co/storage/v1/object/public/blog-images/organization-48457/1785522367413_qualitum.jpg)

- Our [Validate·AI and Operate·AI](https://qualitum.ai/platform) product lines automate evidence generation and keep traceability intact through configuration changes.
- Our platform is designed to save significant time in authoring compared to manual validation documentation.
- Our platform deploys privately within your infrastructure, with customer-managed encryption and zero data egress, details we lay out on our [security page](https://qualitum.ai/security).

If your team is heading into an inspection window or just tired of rebuilding the RTM by hand, [book a working session](https://qualitum.ai/book) with us or start with a Pilot to see how the evidence holds together before you commit further.

## FAQ

### What makes a SaaS deployment "validated" in GxP terms?

A validated SaaS deployment has documented, risk-based evidence that the system meets its intended use, including an approved URS, a traceability matrix linking requirements to executed tests, and audit trails that meet ALCOA+ expectations. The regulated user owns this evidence even when a vendor hosts the platform.

### Does 21 CFR Part 11 apply to every SaaS feature we use?

No, Part 11 applies only where a predicate rule requires the specific record in question, so the starting point is identifying which records fall under existing regulations. The full text of Part 11 sets out the controls that apply once that threshold is met.

### How does FDA's CSA guidance change validation effort?

FDA's Computer Software Assurance approach lets teams size validation effort to risk and intended use rather than applying maximum documentation to every feature, provided the reasoning is documented. The CSA guidance still expects assurance for anything affecting record integrity or product quality.

### What's the single most common reason a validation package fails inspection?

An RTM with broken or missing links between requirements and executed tests is the most frequent failure point, since inspectors treat an untraceable test as invalid evidence. Audit trails that exist but were never actually reviewed are a close second.

### Can automation reduce the manual burden of SaaS validation?

Yes, platforms that author validation artifacts and apply integrity checks at both write-time and review-time can reduce authoring time substantially. Our [Validate·AI platform](https://qualitum.ai/platform/) is designed to save significant time in authoring compared to manual documentation methods.

## Sources

- [Computer Software Assurance for Production and Quality System Software (FDA)](https://www.fda.gov/media/188844/download)
- [eCFR :: 21 CFR Part 11 -- Electronic Records; Electronic Signatures](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11)
- [ISPE GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition)](https://guidance-docs.ispe.org/doi/book/10.1002/9781946964571)

## Authoritative guidance to consult directly

Build your validation package against primary sources, not summaries. Start with Annex 11's draft revision, FDA's CSA guidance, 21 CFR Part 11, and ISPE GAMP 5 before finalizing any validation strategy or responding to inspection findings.

## Recommended

- [Part 11 Compliance: Inspection-Ready Checklist for QA Teams](https://blog.qualitum.ai/part-11-compliance)
- [Qualification vs Validation: A Practical Guide for Pharma QA](https://blog.qualitum.ai/qualification-vs-validation)
- [Data Integrity by Design: A Pharma QA Playbook](https://blog.qualitum.ai/data-integrity-by-design)
- [5 Readiness Checks Pharma IQ Checklists Need for Audit Ready OQ Handover](https://blog.qualitum.ai/iq-checklist-pharma)

## FAQ
### What makes a SaaS deployment "validated" in GxP terms?
A validated SaaS deployment has documented, risk-based evidence that the system meets its intended use, including an approved URS, a traceability matrix linking requirements to executed tests, and audit trails that meet ALCOA+ expectations. The regulated user owns this evidence even when a vendor hosts the platform.

### Does 21 CFR Part 11 apply to every SaaS feature we use?
No, Part 11 applies only where a predicate rule requires the specific record in question, so the starting point is identifying which records fall under existing regulations. The full text of Part 11 sets out the controls that apply once that threshold is met.

### How does FDA's CSA guidance change validation effort?
FDA's Computer Software Assurance approach lets teams size validation effort to risk and intended use rather than applying maximum documentation to every feature, provided the reasoning is documented. The CSA guidance still expects assurance for anything affecting record integrity or product quality.

### What's the single most common reason a validation package fails inspection?
An RTM with broken or missing links between requirements and executed tests is the most frequent failure point, since inspectors treat an untraceable test as invalid evidence. Audit trails that exist but were never actually reviewed are a close second.

### Can automation reduce the manual burden of SaaS validation?
Yes, platforms that author validation artifacts and apply integrity checks at both write-time and review-time can reduce authoring time substantially. Our Validate·AI platform is designed to save significant time in authoring compared to manual documentation methods.
